Какова цена за AlloVir, Inc. (ALVR)

Цена за AlloVir, Inc. (ALVR) Это $9.81

Какова рыночная капитализация для AlloVir, Inc. (ALVR)

Рыночная капитализация для AlloVir, Inc. (ALVR) Это $48.68M

AlloVir, Inc. (ALVR) Коэффициент P/B

AlloVir, Inc. is a biotechnology company in the clinical stage, dedicated to researching and developing allogeneic, "off-the-shelf" multi-virus specific T-cell (VST) therapies. Its primary goal is to prevent and treat severe diseases caused by viral infections. The company's lead product, posoleucel, is an allogeneic, ready-to-use VST therapy designed to combat several significant viruses, including BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Beyond this flagship candidate, AlloVir's pipeline features additional investigational treatments in various stages of development. These include ALVR106, which targets respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109, developed to address SARS-CoV-2 and COVID-19; ALVR107, for treating hepatitis B; and ALVR108. Established in 2013, the company was initially known as ViraCyte, Inc. before officially rebranding as AlloVir, Inc. in May 2019. Its headquarters are located in Waltham, Massachusetts.

Год	P/B	Изменить
2026 (TTM)	1.68	320.88%
2024	0.40	0.00%
2023	0.00	0.00%
2022	0.00	0.00%

Год

P/B

Изменить

2026 (TTM)

1.68

320.88%

2024

0.40

0.00%

2023

0.00

0.00%

2022

0.00

0.00%

Компания	P/B	Разница P/B	Страна
Vertex Pharmaceuticals Incorporated VRTX.US	6.3419	276.71%	US
Argenx SE ARGX.US	6.2413	270.73%	NL
CSL Limited CSL.AX	2.5054	48.82%	AU
Lonza Group AG LONN.SW	-	-	CH
Moderna, Inc. MRNA.US	3.7087	120.30%	US

Компания

P/B

Разница P/B

Страна